{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T12:12:48Z","timestamp":1784117568684,"version":"3.55.0"},"reference-count":58,"publisher":"Informa UK Limited","issue":"10","license":[{"start":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T00:00:00Z","timestamp":1781222400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/doi.org\/10.1080\/policies-text-data-mining"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Opinion on Pharmacotherapy"],"published-print":{"date-parts":[[2026,7,3]]},"DOI":"10.1080\/14656566.2026.2689163","type":"journal-article","created":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T05:40:38Z","timestamp":1781242838000},"page":"967-978","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":0,"title":["Suzetrigine and the emergence of selective NaV1.8 inhibition in acute pain pharmacotherapy: efficacy, safety, and future clinical positioning"],"prefix":"10.1080","volume":"27","author":[{"given":"Wajid","family":"Zaman","sequence":"first","affiliation":[{"name":"Yeungnam University","place":["Gyeongsan, Republic of Korea"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asma","family":"Ayaz","sequence":"additional","affiliation":[{"name":"Ningbo University","place":["Ningbo, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2026,6,12]]},"reference":[{"key":"e_1_3_3_3_1","doi-asserted-by":"publisher","DOI":"10.1097\/TA.0000000000004193"},{"key":"e_1_3_3_4_1","unstructured":"Pain IAftSo. Acute pain. IASP; 2021 [cited 2026 May 7]. Available from: https:\/\/www.iasp-pain.org\/resources\/topics\/acute-pain\/"},{"key":"e_1_3_3_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanwpc.2023.100822"},{"key":"e_1_3_3_6_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-0038-1676477"},{"key":"e_1_3_3_7_1","unstructured":"World Health O. Patient safety WHO. WHO; 2023 [cited 2026 May 7]. Available from: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/patient-safety"},{"key":"e_1_3_3_8_1","doi-asserted-by":"publisher","DOI":"10.1097\/PR9.0000000000001075"},{"key":"e_1_3_3_9_1","doi-asserted-by":"publisher","DOI":"10.1002\/ejp.2024"},{"key":"e_1_3_3_10_1","doi-asserted-by":"publisher","DOI":"10.1097\/ACO.0000000000001599"},{"key":"e_1_3_3_11_1","volume-title":"Nonsteroidal anti-inflammatory drugs (NSAIDs)","author":"Ghlichloo I","year":"2026","unstructured":"Ghlichloo I, Gerriets V. Nonsteroidal anti-inflammatory drugs (NSAIDs). Treasure Island (FL): StatPearls Publishing; 2026."},{"key":"e_1_3_3_12_1","doi-asserted-by":"publisher","DOI":"10.3390\/ph14111091"},{"key":"e_1_3_3_13_1","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.rr7103a1"},{"key":"e_1_3_3_14_1","doi-asserted-by":"publisher","DOI":"10.1097\/ALN.0000000000005460"},{"key":"e_1_3_3_15_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40122-024-00697-0"},{"key":"e_1_3_3_16_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2209870"},{"key":"e_1_3_3_17_1","unstructured":"Administration USFa D. FDA approves novel non-opioid treatment for moderate to severe acute pain. 2025."},{"key":"e_1_3_3_18_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1001411"},{"key":"e_1_3_3_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(99)03313-9"},{"key":"e_1_3_3_20_1","unstructured":"WHO. Opioid overdose: WHO. 2025 [cited 2026 May 7]. Available from: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/opioid-overdose"},{"key":"e_1_3_3_21_1","unstructured":"Consortium IDP. Access without excess: how to ensure safe balanced access to controlled medicines around the world - call for contributions. 2026 [cited 2026 May 7]."},{"key":"e_1_3_3_22_1","doi-asserted-by":"publisher","DOI":"10.3109\/15360288.2011.599485"},{"key":"e_1_3_3_23_1","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2025.1659490"},{"key":"e_1_3_3_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpain.2010.11.006"},{"issue":"2","key":"e_1_3_3_25_1","first-page":"131","article-title":"Acetaminophen-induced hepatotoxicity: a comprehensive update","volume":"4","author":"Yoon E","year":"2016","unstructured":"Yoon E, Babar A, Choudhary M, et al. Acetaminophen-induced hepatotoxicity: a comprehensive update. J Clin Transl Hepatol. 2016;4(2):131\u2013142.","journal-title":"J Clin Transl Hepatol"},{"key":"e_1_3_3_26_1","doi-asserted-by":"publisher","DOI":"10.1177\/0003134820952834"},{"issue":"12","key":"e_1_3_3_27_1","first-page":"1371","article-title":"NSAID prescribing precautions","volume":"80","author":"Risser A","year":"2009","unstructured":"Risser A, Donovan D, Heintzman J, et al. NSAID prescribing precautions. Am Fam Physician. 2009;80(12):1371\u20131378.","journal-title":"Am Fam Physician"},{"key":"e_1_3_3_28_1","doi-asserted-by":"publisher","DOI":"10.1080\/03007995.2022.2049551"},{"key":"e_1_3_3_29_1","doi-asserted-by":"publisher","DOI":"10.2147\/JPR.S526851"},{"key":"e_1_3_3_30_1","unstructured":"Halsey G. FDA approves Journavx first-in-class nonopioid analgesic for moderate-to-severe acute pain. Patient Care (Online). 2025 5 June 2026 https:\/\/www.patientcareonline.com\/view\/fda-approves-journavx-first-in-class-nonopioid-analgesic-for-moderate-to-severe-acute-pain."},{"key":"e_1_3_3_31_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-025-02178-w"},{"issue":"4","key":"e_1_3_3_32_1","first-page":"90","article-title":"Suzetrigine mechanism, efficacy, and clinical implications: a narrative review","volume":"5","author":"Shallof NM","year":"2025","unstructured":"Shallof NM, Abduelkarem AR. Suzetrigine mechanism, efficacy, and clinical implications: a narrative review. Mediterranean J Pharm Pharm Sci. 2025;5(4):90\u201395.","journal-title":"Mediterranean J Pharm Pharm Sci"},{"key":"e_1_3_3_33_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2503570122"},{"key":"e_1_3_3_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2021.107984"},{"key":"e_1_3_3_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2020.107581"},{"key":"e_1_3_3_36_1","doi-asserted-by":"publisher","DOI":"10.54299\/tmed\/mzhz6909"},{"key":"e_1_3_3_37_1","doi-asserted-by":"publisher","DOI":"10.1080\/15360288.2026.2624502"},{"key":"e_1_3_3_38_1","doi-asserted-by":"publisher","DOI":"10.1111\/cts.70414"},{"key":"e_1_3_3_39_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.NPR.0000000000000406"},{"key":"e_1_3_3_40_1","doi-asserted-by":"publisher","DOI":"10.55971\/EJLS.1747184"},{"key":"e_1_3_3_41_1","doi-asserted-by":"publisher","DOI":"10.3390\/ddc4030032"},{"key":"e_1_3_3_42_1","doi-asserted-by":"publisher","DOI":"10.2147\/JPR.S509144"},{"key":"e_1_3_3_43_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.adaj.2024.10.014"},{"key":"e_1_3_3_44_1","doi-asserted-by":"publisher","DOI":"10.1002\/hsr2.71545"},{"key":"e_1_3_3_45_1","doi-asserted-by":"publisher","DOI":"10.18553\/jmcp.2025.31.7.729"},{"key":"e_1_3_3_46_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11916-026-01472-w"},{"key":"e_1_3_3_47_1","unstructured":"Neurology E-i-CM. Suzetrigine San Diego: MedLink neurology. 2025 [cited 2026 May 8]. Available from: https:\/\/www.medlink.com\/articles\/suzetrigine"},{"key":"e_1_3_3_48_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40267-026-01216-1"},{"key":"e_1_3_3_49_1","doi-asserted-by":"publisher","DOI":"10.4062\/biomolther.2025.046"},{"key":"e_1_3_3_50_1","unstructured":"Shanu-Wilson J. Hypha discovery [Internet]. 2025 [cited 2026]. Available from: https:\/\/www.hyphadiscovery.com\/blog\/cyp3a-mediated-metabolism-of-suzetrigine\/"},{"key":"e_1_3_3_51_1","doi-asserted-by":"publisher","DOI":"10.3344\/kjp.26057"},{"key":"e_1_3_3_52_1","doi-asserted-by":"publisher","DOI":"10.1097\/ACO.0000000000001626"},{"key":"e_1_3_3_53_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40261-023-01289-0"},{"key":"e_1_3_3_54_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.acepjo.2026.100337"},{"key":"e_1_3_3_55_1","doi-asserted-by":"publisher","DOI":"10.1177\/10499091251353455"},{"key":"e_1_3_3_56_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms26209865"},{"key":"e_1_3_3_57_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41587-025-02590-3"},{"key":"e_1_3_3_58_1","unstructured":"Roy S. US FDA approves Vertex\u2019s non-opioid painkiller: Reuters. 2025 [cited 2026 May 8]. Available from: https:\/\/www.reuters.com\/business\/healthcare-pharmaceuticals\/us-fda-approves-vertexs-non-opioid-painkiller-2025-01-30\/"},{"key":"e_1_3_3_59_1","doi-asserted-by":"publisher","DOI":"10.4103\/sja.sja_602_25"},{"key":"e_1_3_3_60_1","unstructured":"Pharmaceuticals V. Vertex reports third quarter 2025 financial results. 2025. p. 1\u201311."}],"container-title":["Expert Opinion on Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14656566.2026.2689163","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.tandfonline.com\/doi\/full-xml\/10.1080\/14656566.2026.2689163","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14656566.2026.2689163","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T11:37:50Z","timestamp":1784115470000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/14656566.2026.2689163"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,12]]},"references-count":58,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,7,3]]}},"alternative-id":["10.1080\/14656566.2026.2689163"],"URL":"https:\/\/doi.org\/10.1080\/14656566.2026.2689163","relation":{},"ISSN":["1465-6566","1744-7666"],"issn-type":[{"value":"1465-6566","type":"print"},{"value":"1744-7666","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,12]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ieop20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ieop20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2026-05-08","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-06-10","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-06-12","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}